Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay by Hall, Justin et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2017-09-21 
Discovery of PF-06928215 as a high affinity inhibitor of cGAS 




Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Enzymes and Coenzymes Commons, Immune System Diseases Commons, Immunity 
Commons, and the Immunoprophylaxis and Therapy Commons 
Repository Citation 
Hall J, Golenbock DT, Latz E. (2017). Discovery of PF-06928215 as a high affinity inhibitor of cGAS 
enabled by a novel fluorescence polarization assay. Open Access Articles. https://doi.org/10.1371/
journal.pone.0184843. Retrieved from https://escholarship.umassmed.edu/oapubs/3270 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH ARTICLE
Discovery of PF-06928215 as a high affinity
inhibitor of cGAS enabled by a novel
fluorescence polarization assay
Justin Hall1*, Amy Brault1, Fabien Vincent1, Shawn Weng2, Hong Wang1, Darren Dumlao1,
Ann Aulabaugh1, Dikran Aivazian3, Dana Castro3, Ming Chen1, Jeffrey Culp1, Ken Dower4,
Joseph Gardner5, Steven Hawrylik1, Douglas Golenbock6, David Hepworth7, Mark Horn3,
Lyn Jones7, Peter Jones7, Eicke Latz6,8, Jing Li7, Lih-Ling Lin4, Wen Lin1, David Lin1,
Frank Lovering7, Nootaree Niljanskul1, Ryan Nistler2, Betsy Pierce1, Olga Plotnikova1,
Daniel Schmitt1, Suman Shanker1, James Smith1, William Snyder3, Timothy Subashi1,
John Trujillo1, Edyta Tyminski2, Guoxing Wang2, Jimson Wong1, Bruce Lefker7,
Leslie Dakin7, Karen Leach2
1 Medicine Design, Pfizer, Groton, Connecticut, United States of America, 2 Pfizer Centers for Therapeutic
Innovation (CTI), Boston, Massachusetts, United States of America, 3 Pfizer Centers for Therapeutic
Innovation (CTI), San Diego, California, United States of America, 4 Inflammation and Immunology, Pfizer,
Cambridge, Massachusetts, United States of America, 5 External Research Solutions, Pfizer, Groton,
Connecticut, United States of America, 6 University of Massachusetts Medical School, Worcester,
Massachusetts, United States of America, 7 Medicine Design, Pfizer, Cambridge, Massachusetts, United
States of America, 8 Institute of Innate Immunity, University Hospitals Bonn, Bonn, Germany
* justin.hall@pfizer.com
Abstract
Cyclic GMP-AMP synthase (cGAS) initiates the innate immune system in response to cyto-
solic dsDNA. After binding and activation from dsDNA, cGAS uses ATP and GTP to synthe-
size 20, 30 -cGAMP (cGAMP), a cyclic dinucleotide second messenger with mixed 20-50 and
30-50 phosphodiester bonds. Inappropriate stimulation of cGAS has been implicated in auto-
immune disease such as systemic lupus erythematosus, thus inhibition of cGAS may be of
therapeutic benefit in some diseases; however, the size and polarity of the cGAS active site
makes it a challenging target for the development of conventional substrate-competitive
inhibitors. We report here the development of a high affinity (KD = 200 nM) inhibitor from a
low affinity fragment hit with supporting biochemical and structural data showing these mole-
cules bind to the cGAS active site. We also report a new high throughput cGAS fluorescence
polarization (FP)-based assay to enable the rapid identification and optimization of cGAS
inhibitors. This FP assay uses Cy5-labelled cGAMP in combination with a novel high affinity
monoclonal antibody that specifically recognizes cGAMP with no cross reactivity to cAMP,
cGMP, ATP, or GTP. Given its role in the innate immune response, cGAS is a promising
therapeutic target for autoinflammatory disease. Our results demonstrate its druggability,
provide a high affinity tool compound, and establish a high throughput assay for the identifi-
cation of next generation cGAS inhibitors.
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Introduction
The presence of nucleic acids in the cytosol is a danger signal to mammalian cells. This signal
initiates activation of innate immunity pathways resulting in the production of interferons and
cytokines that comprise the host defense [1–3]. Viral and bacterial infections are well-known
sources of foreign RNA and DNA, but self-nucleic acids that have escaped into the cytosol also
trigger immune responses, contributing to Type I interferonopathies such as Aicardi-Gou-
tieres syndrome, and systemic lupus erythematosus (SLE) [4–6].
Cyclic GMP-AMP synthase (cGAS) is the most recently identified member of the family
of cytosolic DNA sensors. Cytosolic cGAS binds dsDNA and in the presence of ATP and
GTP catalyzes the production of the recently characterized second messenger 20, 30- cyclic
AMP-GMP (cGAMP) which then binds to Stimulator of Interferon Genes (STING). The
cGAS /STING dyad appears to be ancient, with homologs co-evolving from unicellular
organisms over 500 million years distant from humans; the strength of the conservation
pressure on the cGAS/STING dyad may be illustrative of their importance to cellular defense
and immunity [7, 8]. In humans, the binding of the cGAS product to STING causes a confor-
mational change resulting in recruitment of TBK1, and interferon-inducible gene activation
and interferon production via IRF3 phosphorylation and nuclear translocation [9–12]. A
number of other cytosolic DNA sensors exist, including Absent in Melanoma 2 (AIM2),
DNA-dependent activator of IRFs (DAI) and IFN-γ-inducible protein 16 (IFI16) but accu-
mulating evidence suggests cGAS is the primary sensor in innate immune activation [13–
17].
Activation of cGAS is important in host defense against pathogens, but uncontrolled activa-
tion of the cGAS pathway has been implicated in autoinflammatory disease. For example,
gain-of-function mutations in STING result in the autoinflammatory disease SAVI (STING-
associated vasculopathy with onset in infancy), characterized by interferonopathy resulting in
skin lesions, interstitial lung disease, and systemic inflammation [18]. Self-DNA normally is
absent from the cytosol due to the primary mammalian exonuclease TREX1. TREX1 is one of
seven human genes whose mutation cause Aicardi-Goutieres syndrome (AGS), a severe
inflammatory disease, and a small percentage of SLE patients have TREX1 mutations [19–21].
TREX1 knockout mice have elevated levels of dsDNA, elevated levels of cGAMP, and display
multiorgan inflammation (especially myocarditis) leading to morbidity [22, 23]. The double
TREX1/cGAS knockout rescues the TREX1 phenotype, demonstrating a key role for cGAS
stimulation in autoinflammation [24, 25]. Elevated levels of cGAMP have been reported
recently in a subset of SLE patients with a more severe disease phenotype (as shown by higher
SLEDAI scores) compared to SLE patients in whom no cGAMP was detected [26]. Taken
together, these results support dysregulation of the cGAS/STING signaling axis in several auto-
immune diseases.
The evidence linking activation of the cGAS pathway to autoimmune disease suggests that
cGAS inhibitors may have therapeutic efficacy. Few inhibitors have been identified, hampered
in part by the lack of sensitive, high throughput screening assays. Although DNA-binding
compounds may indirectly inhibit cGAS activity, to our knowledge no inhibitor shown to
bind directly to the cGAS active site has been reported. To discover cGAS active site inhibitors
we used NMR screening of a fragment library and identified a compound that binds competi-
tively with cGAMP. Structure-based drug design and chemical optimization of the original
fragment hit resulted in a high affinity lead that binds in the nucleotide binding site and inhib-
its cGAS activity. To address the need for screening assays we produced a novel cGAMP mAb
and developed a high throughput FP assay which can detect cGAMP produced by cGAS con-
centrations at levels as low as 10 nM. Taken together our results demonstrate the druggability
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of cGAS, provide a high affinity active site inhibitor and establish a sensitive screening assay
with broad utility for cGAS drug discovery.
Materials and methods
Additional details of the Methods are provided in the Supporting Information. PF-06928215
was synthesized in house according to procedures in the Methods section; PF-06928215 is
commercially available via Sigma-Aldrich (catalog number PZ038). The cGAMP monoclonal
antibody 80–2 (PF-07043030) will be commercially available from Sigma.
ISD DNA (catalog number tlrl-isdn), ATP, GTP, cAMP, cGMP, cGAMP were purchased
from Invivogen, Donkey anti mouse-IgG-HRP from Jackson ImmunoResearch, BD OptEIA
Substrate Reagent Set Cy5 mono NHS ester from GE Healthcare Life Sciences, N,N-diisopro-
pylethylamine from Applied Biosystems, N-methyl-2-pyrrolidone from Applied Biosystems,
trifluoroacetic acid (TFA) from Applied Biosystems and acetonitrile (HPLC grade) from
Fisher Scientific. PPD was purchased from Cambridge Research Biomolecules, BSA from
Thermo Fisher Scientific, Streptavidin from Thermo Fisher Scientific, sodium bicarbonate
from Sigma-Aldrich, dimethyl sulfoxide from Sigma-Aldrich and Slide-A-lyzer cassettes from
Thermo Fisher Scientific.
cGAS activity mass spectrometry assay
cGAS activity was measured in buffer (10 mM Hepes, 140 mM NaCl, 0.01% Tween-20, 5 mM
MgCl2, pH 7.5) containing 1 mM ATP, 0.3 mM GTP, 100 nM ISD DNA (45 bp dsDNA), and
100 nM cGAS in the presence or absence of test compounds. For Km determinations, the con-
ditions were modified to 1 mM ATP and varying amounts of GTP or 0.3 mM GTP and varying
amounts of ATP. The reaction was incubated for 30 minutes at 37˚C and stopped with the
addition of 50 mM EDTA. 2’3’-cGAMP was measured by mass spectrometry analysis. An ear-
lier version of the assay utilized the same buffer and nucleotide conditions but was conducted
in the presence of 1 nM cGAS, 1 nM ISD DNA and carried out for 6 h at 37˚C before being
processed as described above.
Mass spectrometry analysis
50 μl of H2O was added to each 25 μl cGAS reaction (384 well format). The samples were
mixed by briefly vortexing followed by a 10 min, 3000 g centrifugation at room temperature.
2,3 cGAMP was monitored using 1290 Agilent UPLC in conjunction a Sciex 5500 triple-quad-
rupole mass spectrometer in MRM mode. 10 μl of sample was injected on to a 2x30 mm hyper-
carb column (Thermo Scientific) kept at 60˚C with a flow rate of 0.8 ml/min and a loop sweep
time of 20 s. Mobile phase A consisted of 10 mM Ammonium Acetate, pH 10, and Mobile
phase B consisted of 90:10 (Acetonitrile:Acetone 1:1): 10 mM Ammonium Acetate pH 10
+ 0.1% formic acid. The LC gradient used to separate 2,3 cGAMP is as follows: initial condi-
tions: 85% A, 15% B; Time 0.1: 85% A, 15% B; Time 0.2: 30% A, 70% B; Time 0.3: 30% A, 70%
B; Time 0.35: 85% A, 15% B; Time 0.4: 85% A, 15% B. The LC cycle time (time/sample run)
equaled 30 s. The LC eluent was diverted to waste for the initial 12 s before monitoring 2,3
cGAMP via MS-MRM. 2,3 cGAMP was monitored using 3 MRM transitions: 675.1–506.1 m/z
(primary), 675.1–524.3 m/z (secondary), 675.1–136.2 m/z (secondary) with the optimized
parameters: MRM parameters: dp 99 ep 10 ce 36 cxp 10 for the 506.1 transition and dp 99 ep
10 ce 64 cxp 10 for the 524.3 and 136.2 m/z transitions. The substrates ATP and GTP were
monitored as loading controls with the following MRM transitions: 508.1–136.2 (ATP) and
524.0–152.0 (GTP), respectively. ATP and GTP had the following optimized parameters: dp 99
ep 10 ce 64 cxp 10. The mass spectrometer was set with the following parameters: time/MRM:
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50 msec, cycle time: 0.2750 s, delay time: 0, resolution: unit/unit, pause between mass range:
5.007 msec, curtain gas: 35, collision gas: 10, ion spray voltage: 5500 temp: 600˚C, ion source
gas 1: 60, ion source gas 2: 60. The data was processed using Sciex’s Multiquant 3.0.
cGAMP mAb
All animal work, care, and housing was provided by ProSci Incorporated Mice were provided
daily veterinary supervision and care; bleedings were performed without analgesics, Fatal-Plus
was used for euthanasia. Mice were 8 week old at immunization, 5 A/J mice and 5 SJL/J mice
(The Jackson Laboratory) were injected with a 2:1 mixture of the cGAMP compounds linked
at the adenine NH2, PPD-cGAMP and Streptavidin-cGAMP, and Complete Freud’s Adjuvant,
subcutaneously, for the first immunization only. The mice were subsequently boosted three
more times as above, except with Incomplete Freund’s Adjuvant, spaced every three weeks.
Mouse sera titers were determined by screening for binding to cGAMP-BSA derivatives coated
on a plate in a DELFIA immunoassay (Perkin Elmer). Once a high titer was detected the
mouse selected for fusion was given an intraperitoneal final boost with a 2:1 mixture of the two
cGAMP analogues above, no adjuvant, four days prior to the fusion. Hybridomas were derived
by a fusion of mouse splenocytes from a high titer mouse with the mouse myeloma cell NS-1
(ATCC). Mouse spleen cells were isolated, the red blood cells were lysed in Red Blood Cell lys-
ing buffer (Sigma), and the splenocytes were depleted of B cells expressing surface IgM by
using magnetically labeled anti-mouse IgM micro beads (MAC Miltenyl Biotec). The cells
were washed twice in IMDM media (Gibco) and pelleted with the NS-1 cells at a 4:1 ratio. A
solution of 50% PEG (Sigma) was added to the pellet with gentle shaking. The cells were plated
in 96 well plates in IMDM media containing HAT for one week before the hybridomas were
screened.
cGAMP antibody production and purification
Hybridoma supernatants were screened for binding to BSA-cGAMP derivatives by DELFIA
immunoassay. Specificity for cGAMP over cAMP and cGMP was determined by DELFIA
using biotin-cAMP (Biotium) and biotin-cGMP (Biotium) on streptavidin assay plates
(Pierce). Hybridomas specific for cGAMP were cloned one time by limiting dilution and
expanded for antibody production. The hybridomas were grown in IMDM culture media con-
taining low IgG fetal bovine serum (Hyclone). Antibodies were purified from conditioned
hybridoma media by protein A/G chromatography followed by size-exclusion chromatogra-
phy. Samples were concentrated to approximately 5mg/mL and dialyzed against 20 mM
HEPES, 150 mM NaCl, pH 7. Final samples were analyzed for percent monomer, percent
purity, concentration and stability after one freeze-thaw.
cGAMP ELISA assays
Costar high binding plates were coated with BSA-cGAMP (50 ng/well) in PBS (without cal-
cium or magnesium) and incubated overnight at 4˚C. Plates were washed with buffer (TBS
containing 0.05% Tween-20) and blocked for 2 hr at room temperature with Assay buffer
(TBS containing 0.05% Tween 20 and 1% BSA) followed by washing. cGAMP mAb (diluted in
assay buffer) was added to plates for 1 hr, followed by washing and incubation with donkey
anti-mouse IgG-HRP for an additional hr. After washing, plates were developed with sub-
strate, the reaction was stopped with 2 N H2SO4 and OD was read at 450 nm. The competition
ELISA assays followed the same procedure, with the exception that 40 ng/ml anti-cGAMP
mAb was preincubated with various concentrations of cGAMP, ATP or GTP for 1 hr prior to
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addition to the BSA-cGAMP assay plates. After incubation for 1 hr, plates were washed, incu-
bated with secondary antibody, and developed as described above.
Cy5-cGAMP fluorescence polarization assay
cGAS activity was measured in buffer (10 mM Hepes, 140 mM NaCl, 0.01% Tween-20, 5 mM
MgCl2, pH 7.5) containing 1 mM ATP, 0.3 mM GTP, 100 nM ISD DNA (45 bp dsDNA), and
100 nM cGAS. For inhibition assays, compounds were included in the reaction, and after incu-
bation for 1 h at room temperature, reactions were stopped with 50 mM EDTA followed by
addition of Cy5-labeled cGAMP (2 nM) and 16 nM cGAMP antibody. After incubation for 1
h at room temperature, plates were read on an Envision plate reader (excitation: 620 nm; emis-
sion: 688 nm). Determination of the Ki of cGAMP for mAb 80–2 was conducted with the fol-









Characterization of cGAS enzymatic activity
In the presence of ATP, GTP and dsDNA, cGAS catalyzes the production of the novel second
messenger cGAMP. cGAMP levels can be measured directly via mass spectrometry, and we
initially used this medium-throughput format to establish enzyme assay conditions after
optimizing incubation time, and the concentration of DNA, substrates and enzyme (Fig 1A–
1C). Briefly, cGAMP was separated from enzymatic assay reaction using liquid chromatogra-
phy and its levels measured using mass spectrometry. Human cGAS (aa 2–522) produced
and purified from Sf9 cells displayed concentration-dependent increases in cGAMP produc-
tion. cGAS activity was typically measured using 100 nM enzyme though concentrations as
low as 1 nM resulted in detectable levels of cGAMP. The assay was linear for over 6 hr at
37˚C and a 30 min reaction time was used routinely for testing compounds at the 100 nM
enzyme concentration. As expected, cGAS activity was dependent on dsDNA; with 1 nM
cGAS, an EC50 value of 1 nM was obtained for dsDNA suggesting a high affinity interaction.
Higher cGAS concentrations required stoichiometrically higher DNA concentrations for
maximal activation (data not shown). We generally used the 100 nM cGAS assay as we found
the 1 nM version was prone to a high false positive rate. For example, the 1 nM cGAS assay
conducted with 1 nM dsDNA was very sensitive to inhibition by metals (including copper
and palladium) commonly used as catalysts in chemical synthesis while zinc addition lead to
increased enzymatic activity (Fig 1D and S1 Fig). This high false positive rate was signifi-
cantly reduced using 100 nM cGAS with 100 nM dsDNA though hit re-purification or re-
synthesis was essential for validation.
cGAS requires both ATP and GTP for catalysis but the Km values for the nucleotides have
not been reported to date. Apparent Km values were determined by varying the concentration
of one nucleotide in the assay while keeping the other nucleotide fixed (S2 Fig). The fixed con-
centrations of ATP and GTP roughly approximated physiological levels at 1 mM and 300 μM,
respectively. Enzymatic activity increased sharply with increasing nucleotide concentrations,
while concentrations greater than 1 mM resulted in decreased cGAMP production, consistent
with substrate inhibition. Under these conditions the apparent Km values were similar, 30 μM
for GTP and 35 μM for ATP. We have carried out a deeper kinetic study of the cGAS mecha-
nism using multiple assay formats which we report in detail elsewhere (manuscript submitted),
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and our general results are in agreement with the apparent Km and substrate inhibition effects
we describe here.
Development of a high throughput cGAS fluorescence polarization
assay
The mass spectrometry assay has the advantage of directly measuring the cGAMP product, but
it is generally a slower and more resource-intensive medium-throughput assay. Therefore, to
enable high throughput screening capabilities of larger compound sets we developed a fluores-
cence-based assay that could be utilized to screen for cGAS inhibitors. The FP assay requires
an antibody specific for cGAMP as well as a fluorescently labelled cGAMP analog. As such, an
ethylenediamine-cGAMP analog (Compound 11) was synthesized as a versatile intermediate
that enabled antibody generation (S3 Fig).
A number of different cGAMP conjugates were synthesized for mouse immunizations and
antibody screening (S4 Fig and Supporting Information). Mice were immunized with a mix-
ture of cGAMP-PPD and cGAMP-SA, and serum was tested in a DELFIA immunoassay for
reactivity against a further analog, cGAMP-BSA. This screening and immunization strategy
allowed for the selection of mAbs that specifically recognized cGAMP while excluding mAbs
against either the PPD and biotin-streptavidin conjugates, or the PEG linkers.
Hybridomas were derived from mice with positive titers, and supernatants were screened
against cGAMP-BSA. Selectivity for cGAMP was an important requirement for the final mAb
and therefore positive supernatants were counterscreened against biotin-cAMP and biotin-
Fig 1. Characterization of cGAS enzyme activity. Measurement of cGAMP production was conducted by
LC-MS as described in Methods. (A) Time course of cGAS (15 nM) activity; (B) titration of dsDNA activation of
cGAS (1nM) activity; (C) cGAS enzyme titration; (D) inhibition of cGAS (1 nM) activity by CuBr.
https://doi.org/10.1371/journal.pone.0184843.g001
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cGMP. Hybridomas specific for cGAMP were cloned by limiting dilution, and mAb 80–2 was
selected for further characterization and FP assay development. In an ELISA assay against
BSA-cGAMP, mAb 80–2 displayed an EC50 value of 40 pM and was specific for cGAMP as
demonstrated in competition experiments with ATP, GTP, cAMP and cGAMP (S5 Fig and
data not shown).
For the FP competition assay, the ethylenediamine-cGAMP (11) was labelled through the
primary amine with Cy5, a long wavelength fluorescent dye. Titration of mAb 80–2 with 2 nM
Cy5-cGAMP demonstrated an EC50 of ~8 nM; 2 nM Cy5-cGAMP and 16 nM mAb 80–2 were
chosen as the optimal concentrations for the cGAS assay (Fig 2A). Cy5-cGAMP binding to
mAb 80–2 was specific, and was competed by cGAMP, but not by ATP, GTP, cAMP or cGMP
(Fig 2B). This demonstration of specificity was critical to establish since ATP and GTP are
high concentration substrates in the cGAS enzyme assay and could potentially interfere with
the FP signal. The fluorescence polarization data does suggest that the significantly higher
affinity observed in the ELISA assay (40 pM) is likely an overestimation of antibody affinity.
Additionally, as cGAMP displayed a Ki of 76 nM (Fig 2B) for mAb 80–2 in competition mode,
we cannot rule out that this antibody may recognize the linker region in addition to cGAMP
itself. Nonetheless, the assay was established and optimized in 384-well format, with a Z0 of
>0.5 and a robust signal/background of>80 mP (Fig 2C). A screen of forty thousand com-
pounds at a final concentration of 100 μM displayed a normal distribution for the frequency of
compound inhibition (Fig 2D). Additionally, a test set of approximately 40 compounds includ-
ing initial fragment hits and related compounds that showed activity in the mass spectrometry
assay was used to validate the FP assay; there was less than 3-fold variation in the IC50 values
obtained between the mass spectrometry method and the FP assay (data not shown). The FP
assay has several advantages compared to the more resource intensive mass spectrometry
approach and proved to be a high throughput, rapid and robust assay for detecting cGAS
inhibitors in an enzyme assay. Recently, a riboswitch cGAMP biosensor has been reported
that was proposed to be suitable for high throughput screening (HTS) and used to quantify
micromolar cellular cGAMP levels in cells overexpressing cGAS [28]. We attempted to utilize
the FP assay format to detect cGAMP levels in dsDNA-stimulated THP-1 cells, but were not
able to reproducibly measure cellular cGAMP using this approach (data not shown). Overall,
these results demonstrate the utility of mAb 80–2 and the FP assay for HTS purposes while
they also highlight their limitations in terms of measurement of endogenous cGAMP levels in
primary human cells.
Discovery and optimization of an active site inhibitor
The catalytic mechanism of cGAMP formation by cGAS has been reported previously. Briefly,
ATP and GTP are simultaneously bound, dsDNA activates cGAS and selectively orients sub-
strates through Thr211 and Arg376 (Homo sapiens numbering) at the guanine base [29] and the
adenine ribose through Asp227 [30] while priming catalysis at the ATP α-phosphate and the 2
´-OH of the guanine ribose to form the linear GTP-2´-3´-AMP intermediate. The intermedi-
ate must flip over to allow a similar catalytic event to occur between the guanine 5´-α-phos-
phate and the 3´-OH of the adenine ribose, making the final cyclic dinucleotide 2´,3´-cGAMP
[31]. cGAS can accommodate the rearrangements of the intermediates because the active site
is both large and polar, which can present challenges to the identification and optimization of
high affinity small molecule ligands and inhibitors. Consistent with this observation, computa-
tional scoring of the cGAS active site using several different methods [32–34] suggests this
pocket is marginally druggable (data not shown).
High affinity inhibitor of cGAS
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Nonetheless, despite its relatively open and polar character, the cGAS active site is calcu-
lated to be the most druggable pocket on the protein. In an effort to identify cGAS ligands we
undertook a saturation transfer difference (STD) 1H NMR screen of the Pfizer fragment library
against a previously crystalized cGAS construct beginning at residue 161 (cGAS161) (H. sapiens
numbering); details of the library and general strategy have been described previously [35]. To
identify the active site ligands we subsequently rescreened the initial binders in the presence of
2´,3´-cGAMP and prioritized those that displaced the enzymatic product. The resulting frag-
ments were then tested for binding affinity to cGAS by SPR in the absence of activating
dsDNA. Finally, we attempted to obtain structures of the tightest binders to cGAS161. Com-
pound 15 was identified via the NMR screen, and SPR demonstrated that it bound directly to
cGAS, although with low affinity (KD = 171 μM) (Figs 3, 4A and 4B). In the FP assay, com-
pound 15 was detected as a weak inhibitor, with an IC50 of 78 μM against cGAS enzymatic
activity.
The X-ray structure of compound 15 confirmed that it binds in the active site of cGAS (Fig
4C and S1 Table for crystallographic statistics). The binding site of 15 is formed between the
plane of the phenyl ring of Tyr436 and the guanidyl group of Arg376. Based on published X-ray
structures of cGAS, compound 15 is occupying a similar region of the adenine base binding
site of ATP [30] or 2´,3´-cGAMP (see PDB 4K9B [31] and 4O67 [36]).
The tetrazole-containing biaryl ring of compound 15 accounts for the majority of the inter-
action with Tyr436 and Arg376, yet modification or deletion of the phenyl ring of compound 15
resulted in complete ablation of binding suggesting an important role for the phenyl moiety in
compound affinity (data not shown). The requirement of the phenyl of compound 15 may be
Fig 2. Characterization of cGAMP FP assay. (A) mAb titration with Cy5-cGAMP (2 nM); (B) competition of
Cy5-cGAMP (2 nM) binding to mAb 80–2 with: cGAMP, cAMP, cGMP, ATP or GTP; (C) Z’ results of FP assay
in subset screen; (D) Distribution of compound activity from subset screen.
https://doi.org/10.1371/journal.pone.0184843.g002
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the result of an edge-face interaction of the phenyl with the side-chain of Phe488 (ca 3.35 A˚
´
). In
fact, the electron density of 15 suggests the phenyl is coplanar with the tetrazolopyrimidine
aromatic core. In order to maintain a reasonable torsional strain of this co-planarity the phe-
nolic tautomer of 15 (OH) is likely the preferred tautomer in the bound state (Fig 4D, 15a).
Compound 15 was pursued further due to its high ligand efficiency and competition with 2
´,3´-cGAMP. However, it was discovered upon attempted resynthesis that this compound is
not chemically stable and readily isomerizes via an open-ring azidopyrimidine (S5 Fig) [37].
From a chemical optimization perspective this was not attractive and thus several chemically
stable [6,5] ring systems were synthesized in an attempt to find a core that would recapitulate
the active pharmacophore and not isomerize. In this process we found the original tetrazolo-
pyrimidine core of 15 could be substituted for a pyrazolopyrimidine (16) which maintained
comparable affinity (KD = 78 μM, and inhibition of cGAS functional activity (IC50 = 69–
125 μM) as the original fragment hit (Fig 3). The X-ray structure of the pyrazolopyrimidine 16
was solved and it bound in a similar manner to the original fragment hit 15. Notably, the
regioisomeric analog 16 was also prepared and it did not demonstrate binding affinity to
Fig 3. Binding affinities and in vitro activities of cGAS inhibitors.
https://doi.org/10.1371/journal.pone.0184843.g003
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Fig 4. Characterization of compound 15 binding to cGAS. (A) 1D 1H spectra of 2´,3´-cGAMP (top) and 1H
STD of 2´,3´-cGAMP interacting with cGAS (bottom). (B) 1D 1H spectra of 2´,3´-cGAMP (orange) and
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cGAS (data not shown). The structure of compound 16 shows the amide substituent on the
pyrazole afforded an attractive vector to explore other regions of the active site. We found that
amides capped with polar functionalities were favored and demonstrated significant increases
in both the SPR affinity and the functional activity of these inhibitors. Compounds 17 and 18
inhibited cGAS activity with IC50 values below 20 μM (Fig 3). Notably, compound 19 and PF-
06928215 have binding affinities of 2.7 and 0.2 μM, respectively, with a corresponding increase
in inhibitory potency in the cGAS assay; PF-06928215 inhibited cGAS activity with an IC50
value of 4.9 μM (Fig 5A). As with our other compounds, there is good agreement between
binding and inhibition, though activity measurements occur in the presences of competing
nucleotides which would cause the IC50 to appear weaker than KD measurements conducted
without nucleotides. Compared to compound 15, PF-06928215 has improved in potency and
displays longer off rate kinetics than any other compound in this series (Figs 4C and 5B).
Despite the progress in biochemical potency, PF-06928215 displayed no activity in cellular
cGAS assays measuring dsDNA-induced IFN-beta expression via a luciferase reporter (Panel
A in S7 Fig). Compounds 17–19 also had no effect on IFN-β induction. Notably, the TBK1
inhibitor BX-395 was used as a positive control, and inhibited induction with an IC50 value of
~ 60 nM. The lack of inhibitory activity of the PF-06928215 and related compounds was not
the result of cytotoxicity, as the compounds had minimal effect on cell viability (Panel B in S7
Fig). The reason(s) for the compounds’ inability to inhibit IFN induction is not known but
considering the high levels of ATP and GTP, it is likely that further improvements in potency
are required for inhibition of cellular cGAS activity. Additionally, to improve this class of bio-
chemical inhibitors improvements to their passive permeability and plasma protein binding
profiles are required. Replacement of the carboxylic acid with an isostere that has a higher
pKa, thus lowering the polar surface area, and reducing the number hydrogen bond donors
are two possible approaches.
Subsequent X-ray structures of PF-06928215 show the alkyl chain interacting with a small
hydrophobic pocket formed between Tyr436 and His437 while the polar head groups prefer to
interact with the polar residues Arg376 and Lys362 above the biaryl core (Fig 5C). In PF-
06928215 the hydrophobic interactions extend to Leu495 and the carboxylate head piece also
interacts with a partially ordered Lys362. Interestingly, when comparing the interactions of
compound PF-06928215 with reported structures of cGAS, we found that the Lys362 interac-
tion of PF-06928215 closely mimics an interaction with Lys350 (Mus. musculus numbering) in
the linear 5´-pG (2´-5´)pA pseudo-intermediate reported by the Patel lab [31] (PDB 4K9A). In
4K9A, Lys350 interacts with an oxygen of the 2´-5´ phosphodiester bond, however in none of
the cyclic dinucleotide structures is this Lys induced to reach the phosphodiester bond. Thus
we speculate that this interaction is particular to how cGAS holds the linear intermediate dur-
ing the catalytic process. PF-06928215 might be mimicking this interaction in the active site
(Fig 5C).
The newly reported dsDNA sensing enzyme cGAS has emerged as a new player in the
innate immunity pathway. Direct genetic links of cGAS to human disease have not been
shown, but gene knockouts in animal models have demonstrated the importance of cGAS in
controlling immune activation. These results have important implications suggesting a role of
cGAS in immune diseases and highlight the need for pharmacological tools to probe cGAS
compound 15 (green) (top) and 1H STD of a mixture of 2´,3´-cGAMP and compound 15 showing compound
15 has out competed 2´,3´-cGAMP for interacting with cGAS (bottom). (C) SPR sensorgram of compound 15
with binding fit inset. (D) Compound 15 in either its hydroxyl (15a) or keto (15b) tautomeric forms. (E) cGAS
active site showing residues that interact with compound 15; Fo-Fc electron density omit map (green) for
compound 15 (brown) is contoured at 3 Sigma and shows all density within 4 Å of compound 15.
https://doi.org/10.1371/journal.pone.0184843.g004
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Fig 5. PF-06928215 is a high affinity cGAS inhibitor. (A) Concentration-dependent inhibition in cGAMP FP
assay. (B) SPR sensorgram of PF-06928215 binding to cGAS, 2-fold variations in the concentration of PF-
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function in cells and animal models. Despite a large and polar active site, our results demon-
strate that active site inhibitors can be identified and chemistry optimization resulted in an
inhibitor with nM binding affinity and μM functional activity. The development of the high
throughput FP assay to measure cGAS activity can be readily utilized for screening large com-
pound sets and should be enabling for the further discovery of potent, cGAS inhibitors with
cellular activity which would be useful in further elucidating the role of this enzyme in disease.
Supporting information
S1 Fig. Modulation of cGAS enzyme activity by metals in the MS assay. (A) Inhibition dose
response of Pd(OAc)2 with cGAS (1 nM); (B) Activation dose response of ZnCl2 with cGAS (1
nM) and ISD dsDNA (1nM); NB: lower activation multiples were observed with higher ISD
DNA concentrations (data not shown); (C) Results from a panel of metal salts tested in the
cGAS (1nM) assay in the presence of 1 nM ISD DNA.
(DOCX)
S2 Fig. Nucleotide-dependence of cGAS enzyme activity. (A) Apparent Km determination
for GTP in the presence of 1 mM ATP; (B) Apparent Km determination for ATP in the pres-
ence of 0.3 mM GTP.
(DOCX)
S3 Fig. Preparation of a cGAMP analog containing an ethylenediamine functionality. A
protected and activated ethylenediamine adenosine analog was prepared (5) and coupled with
a protected guanosine analog (7) in acetonitrile, followed by oxidation to the phosphate (8).
Protecting group manipulation, cyclisation and further oxidation provided the protected
cGAMP analog (9). Stepwise removal of the various protecting groups then provided the
desired ethylenediamine-cGAMP analog (11). Compound 11 proved to be a highly useful
intermediate, whereby the primary alkyl amino group could be selectively reacted with various
linker groups, forming a stable amide bond, followed by subsequent conjugation or binding to
various proteins for antibody generation or screening.
(DOCX)
S4 Fig. cGAMP derivatives for mAb production and screening. (A) An ethylenediamine-
cGAMP analog linked through PEG5 to a reactive NHS ester (13) for subsequent attachment
to PPD (cGAMP-PPD); (B) an ethylenediamine-cGAMP analog linked through PEG6 to a
biotin molecule (14) for subsequent binding to streptavidin (cGAMP-strepavidin) were syn-
thesized. Mice were immunized with a mixture of these protein conjugates. (C) serum was
tested in a DELFIA immunoassay for reactivity against a further analog, ethylenediamine-
cGAMP linked through C6 to a reactive NHS ester (12) which allowed conjugation to BSA
(cGAMP-BSA). (D) an ethylenediamine-cGAMP analog conjugated to Cy5 was synthesized to
be used as the fluorescently labelled cGAMP analogue in the FP assay.
(DOCX)
S5 Fig. cGAMP mAb 80–2 characterization. (A) titration of mAb 80–2 in cGAMP ELISA;
(B) mAb 80–2 was preincubated with cGAMP, ATP or GTP for 1 hr prior to addition to the
cGAMP-BSA coated assay plates. Binding was inhibited in a concentration-dependent manner
06928215 are shown in rainbow registry with kinetic association and dissociation fits in black. (C) cGAS active
site showing residues that interact with PF-06928215, Fo-Fc electron density omit map (green) for PF-
06928215 (brown) is contoured at 3 Sigma and shows all density within 4 Å of PF-06928215. Figure was
generated using Pymol.
https://doi.org/10.1371/journal.pone.0184843.g005
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by cGAMP, but neither ATP nor GTP at mM concentrations inhibited the binding of mAb
80–2 to BSA-cGAMP. Data points are average of duplicate determinations; error bars repre-
sent standard deviation.
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S6 Fig. Compound 15 can readily isomerize via ring opening through an open azidopyri-
midine.
(DOCX)
S7 Fig. Effect of cGAS inhibitors on IFNβ induction. THP-1 Dual cells were pretreated with
various concentrations of BX-795 (red triangles), Compound 17 (yellow squres), Compound
18 (purple triangles), Compound 19 (black triangles) or PF-06928215 (blue circles) for 1 hr fol-
lowed by stimulation with salmon sperm DNA for 12 hrs. Media was collected and analyzed
for luciferase signal (A), and cell viability (B) was analyzed with CellTiter Glo, as described in
Methods.
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S1 Table. Crystallographic data and refinement statistics.
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